Drug Report History
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
Version v3-EN | Version v2-FR | |
---|---|---|
Language | English | French |
Date Updated | 2021-02-02 | 2020-11-26 |
Drug Identification Number | 00786306 | 00786306 |
Brand name | POTASS CHLOR 40MEQ 5% DEX AND 0.9% SOD CHLOR | POTASS CHLOR 40MEQ 5% DEX AND 0.9% SOD CHLOR |
Common or Proper name | 40 MEQ Potassium Chloride in 5% Dextrose and 0.9% Sodium Chloride Injection USP | 40 MEQ Potassium Chloride in 5% Dextrose and 0.9% Sodium Chloride Injection USP |
Company Name | BAXTER CORPORATION | BAXTER CORPORATION |
Ingredients | DEXTROSE SODIUM CHLORIDE POTASSIUM CHLORIDE | DEXTROSE SODIUM CHLORIDE POTASSIUM CHLORIDE |
Strength(s) | 5G 900MG 300MG | 5G 900MG 300MG |
Dosage form(s) | SOLUTION | SOLUTION |
Route of administration | INTRAVENOUS INTRAVENOUS | INTRAVENOUS INTRAVENOUS |
Packaging size | 1000mL, 14 bags/case | 1000mL, 14 bags/case |
ATC code | B05BB | B05BB |
ATC description | I.V. SOLUTIONS | I.V. SOLUTIONS |
Reason for discontinuation | Business reasons | Business reasons |
Anticipated discontinuation date | 2021-02-01 | 2021-02-01 |
Actual discontinuation date | 2021-02-01 | 2021-02-01 |
Remaining supply date | 2021-02-01 | 2021-02-01 |
Discontinuation status | Discontinued | To be discontinued |
Discontinuation decision reversal | no | no |
Tier 3 Status | No | No |
Information on remaining supply | ||
Company comments | We have identified four alternative codes for your consideration: JB1674, JB1434, JB1264, and JB1984 | We have identified four alternative codes for your consideration: JB1674, JB1434, JB1264, and JB1984 |
Health Canada comments |